Environmental controls at Novo Nordisk’s aseptic filling facility in Bagsvaerd, Denmark, are not consistently implemented and may have resulted in distribution of contaminated sterile drugs, an FDA warning letter states.
The warning follows the Danish drugmaker’s inadequate response to two observations made during an inspection of the plant in March 2012, the agency said in a letter.
FDA investigators flagged plant personnel for failing to collect more than 800 scheduled environmental monitoring (EM) samples of sterile drugs over a two-year period. Such collections are critical to any aseptic facility’s environmental program, and the number of samples missed suggests a disconcerting “pattern” of EM laxity at the plant, the letter states.
Even though the FDA has set out at least 20 references to training when it comes to GMPs, the agency’s requirements can be vague, and often lead to uncertainty on the part of both the trainers and the trainees. Don’t get left behind. Update your training!
From Training to Learning: Improving GMP Performance is presented by LearningPlus and FDAnews. This workshop will help you more accurately and efficiently convey your GMP expertise to your team. Sign up now!